Tumor immunology is a field of study focused on understanding the complex interactions between the immune system and cancer cells. However, tumors can develop mechanisms to evade immune detection and destruction. Research in tumor immunology explores various aspects, such as immune checkpoint pathways, tumor antigens, and the tumor microenvironment. Immune checkpoint inhibitors, a class of immunotherapy drugs, target specific proteins that inhibit immune responses, enabling the immune system to better recognize and attack cancer cells. Tumor immunology also investigates the role of immune cells, including T cells, B cells, and natural killer cells, in the antitumor immune response. Understanding the immune landscape of tumors helps develop personalized immunotherapies that harness the patient's immune system to target and destroy cancer cells. Advancements in tumor immunology have led to groundbreaking therapies like CAR-T cell therapy and personalized cancer vaccines. Ongoing research continues to unravel the complexities of tumor-immune interactions, with the goal of developing more effective and targeted immunotherapies for various types of cancer.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States